In order to reach the European market, a new drug needs to receive a positive evaluation regarding its quality, safety and efficacy by regulatory health authorities and also obtain a positive HTA appraisal regarding its cost-effectiveness by HTA bodies. Regulators and HTA bodies are collaborating in several projects at European level in order to harmonize the scientific requirements of both evaluations to the maximum extent possible. The comparison of the regulatory evaluation performed by EMA for Kalydeco and the HTA appraisals issued by several EU bodies exemplifies the dilemma between scientific evidence and local economic considerations and the difficulties in the achievement of harmonization and therefore equity in the access to drugs.
The approval of medicinal products is a highly regulated field. The birth of the unified European legislation of medicines took place in 1965 with the adoption of Directive 65/65/ CEE [1] . The sponsor of any new medicinal product should demonstrate the quality, the safety and the efficacy of a drug prior to being granted the permission by the relevant health authorities to put the product on the market at the disposal of patients. The European Medicines Agency (EMA), the scientific body responsible for performing the evaluation, provides a scientific opinion to the European Commission (EC), which will then serve as the basis for the marketing authorization, which will have automatic validity in all European Union (EU) member states. HTA is taking more and more relevance every day, for authorities, for payers and for industry. Proven quality, safety and efficacy, the three basic guarantees are no longer enough to allow patients access to a new medicine. Now, a medicinal product also has to demonstrate its relative cost-effectiveness, when compared to other available treatments, the so-called fourth guarantee in order to receive
IntroductIon
Health authorities assess the quality, safety and efficacy of a medicinal product 1 based on its own merits whereas Health Technology Assessment (HTA) bodies evaluate the safety and efficacy of a drug comparatively to other available treatments on the market, as well as its cost-effectiveness. As a consequence, industry faces the challenge that the data set required to undertake the two evaluations could not be necessarily the same. In such a context, it is of extreme importance to design correctly from the start the expensive clinical programs with the aim of fulfilling the obligations for the two areas of assessment efficiently and in parallel. European health authorities, including regulatory and HTA bodies, recognizing all these challenges and the existing room for harmonization have initiated the path towards knowledge sharing and collaboration in order to reach and establish common approaches.
Farmeconomia. Health economics and therapeutic pathways 2015; 16 (4) The regulatory and Health Technology processes in Europe and drug market access. The case of cystic fibrosis a positive appraisal by HTA bodies and successful reimbursement negotiations. An important milestone has been reached in Europe in this context with the establishment of the European Union Network of HTA (EU-netHTA) [2] . In 2004, the EC and the Council of the EU recognized the Health Technology Assessment as a high priority and urged for establishing a sustainable European network on HTA. In 2005, a group of 35 organizations throughout Europe began the activities of the EUnetHTA Project. One of the most important milestones achieved by EUnetHTA is the creation of a Core harmonized Model for HTA appraisals, where the key elements to be evaluated by HTA bodies are represented [3] . As a response to the recommendations from the Pharmaceutical Forum in 2008, the EMA and EUnetHTA initiated a collaboration to improve the contribution that European Public Assessment Reports (EPARs) prepared by EMA could make to the assessment of relative effectiveness of medicinal products [4] . The EU Directive 2011/24/EU [5] on the application of patients' rights in cross-border healthcare set a milestone in the recognition of equity in rights across European Union Members States and also introduced important provisions for the EU collaboration in the area of rare diseases and HTA. Kalydeco (ivacaftor), is recognized as being the first in a new class of medicines: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) potentiators. It targets the cystic fibrosis CFTR and so treats the underlying cause of the disease. It increases the time that activated CFTR channels remain open at the cell surface. Kalydeco is one the drugs that has received orphan designation for cystic fibrosis [6] and one of the seven drugs [7] for which the European Medicines Agency has adopted a positive opinion for cystic fibrosis. Kalydeco is at the moment one of the most expensive drugs in Europe. The annual price of the drug per patient makes it difficult to for some national budgets to absorb the cost [8] . The objective of this study was on the one hand to identify the elements that regulators and HTA bodies took into account when performing their respective evaluations of Kalydeco. And, on the other hand, to ascertain the origin of the divergent opinions identified among HTA bodies when confronted with the same clinical evidence.
Methodology
The EPAR for Kalydeco issued by the EMA in 2012 was taken as the reference document for the regulators evaluation [9] .
The publicly available HTA appraisals in English, Spanish and German from European HTA bodies were taken as reference for this analysis. The selected reports correspond to the following HTA bodies 2 : -Scottish Medicines Consortium (SMC) -UK Scotland [10] ; -NHS England statement (NHS) -UK England [11] ; -Therapeutic Positioning Report for Spanish Government (IPT) -Spain [12]; -Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG) -Germany [13] ; -National Center for Pharmacoeconomics (NCPE) -Ireland [14]; -Haute Autorité de Santé (HAS) -France [15] . A comparative analysis of the information contained in the EPAR and the HTA reports was undertaken following the 3 steps scheme described below: 1. Analysis following the HTA Core Model developed by EUnetHTA to determine the domains common to the regulatory and HTA fields; 2. Analysis of the study design elements which are frequently source of discrepancies between regulators and HTA bodies (i.e. comparators, study population and endpoints); 3. Analysis of the clinical evidence elements available pre-approval. The items considered were the benefit/risk balance, post-approval studies, degree of uncertainty and clinical added value. Study of the similarities and differences in the opinions among HTA bodies in view of the same clinical evidence which is taken from the EPAR published by the EMA 3 .
results Each table contains a summary of the information present in the EPAR and HTA reports studied. The EUnetHTA Core Model (Table I) defines the domains that HTA bodies should study for their appraisals. Not all these domains are relevant for the regulatory assessment. In addition, the analysis showed that not all HTA reports considered all domains and also the depth and detail in which the same domains were addressed was different too.
The analyses showed that the clinical study design was considered appropriate in all HTA reports (Table II) . No divergent opinions in this area were pointed out between regulators and HTA bodies. The elements analysed under this area showed differences in opinions among HTA bodies, indicating variations in the acceptance of the degree of uncertainty regarding the long-term safety and efficacy. From the six HTA reports studied, four countries acknowledged the uncertainty present but accepted it. Two bodies, the NCPE of Ireland and the SMC of Scotland did not.
The appraisal of the clinical added value (i.e. relative cost effectiveness) also varies among HTA bodies (Table III) . No discussion at all is present in the French and Spanish reports. In the German report only global budget considerations are present. The English, Scottish and Irish reports address the pharmacoeconomic studies provided by the Sponsor together with Incremental Cost Effectiveness Ratio (ICER) and Quality Adjusted Life Year (QALY) threshold elements in addition to global budget considerations.
Elements

EPar information: What is sought to grant a Marketing Authorization?
HTa reports information: What is sought for pricing and reimbursement?
Health problem and current use D. Main elements of the disease described. 
Clinical effectiveness
D. Observational studies imposed as a condition on the marketing authorization. Details discussed in Tables II and III. nHs: D. Details discussed in Tables II and III . sMC: D. Details discussed in Tables II and III. iPT: D. Details discussed in Tables II and III . nCPE: D. Details discussed in Tables II and III . Has: D. Details discussed in Tables II and III . iQWig: ND.
Costs and economic evaluation
NA. nHs: D. Details discussed in Tables II and III . sMC: D. Details discussed in Tables II and III. iPT: ND. nCPE: D. Details discussed in Tables II and III The Standard of Care (SOC) (i.e. pre-study medication) was continued in the patients with the exception of the inhaled hypertonic saline, which was not allowed. D. The studies mentioned above had 48 weeks of duration. The main measure of efficacy was the ability to improve the pulmonary function (measured as the absolute change from baseline in percent predicted FEV 1 after 24 weeks of treatment). This variable was also measured at week 48. Secondary variables: other beneficial aspects as decrease rate of pulmonary exacerbations, sweat chloride concentration and increase in body weight. In addition, the change in respiratory symptoms at week 24 and 48 evaluated through the validated CFQ-R questionnaire 2 .
PERSIST study (VX08-770-105) is an extension, non-controlled open-label study of studies VX08-770-102 and 103, the two pivotal trials presented for the marketing authorization application. The open-label study is up to 96 weeks (i.e. 144 weeks of treatment for those already on the drug and 96 for those initially allocated to placebo). nHs: D. Improved lung function, weight gain and decrease in worsening of breathing requiring other treatments. Note is made to the absence of long-term efficacy data but it is recognized that the main indicator of cystic fibrosis, the amount of salt in sweat returns to normal values with ivacaftor treatment). nHs: D. Mention to PERSIST study. Mention that health outcomes in patients taking ivacaftor will be monitored using data from the cystic fibrosis registry. sMC: D. Long-term studies are acknowledged. iPT: D. The studies imposed on the MA are acknowledged and recognized as useful to clarify pending long-term safety and efficacy evidence generation. nCPE: ND. Has: Discussed. Based on EPAR. iQWig: ND.
Degree of uncertainty accepted
D. EPAR indicates limited data on longer-term effects.
Conditions were imposed on the MA to provide further data in this respect: From an ongoing long-term study and to conduct a five-year observational study. nHs: D. Good evidence that ivacaftor is clinically effective although long-term safety and effectiveness data beyond 96 weeks are lacking. Monitoring of sweat chloride test required as indicators of treatment effectiveness and used as a stopping criteria for the treatment to be discontinued. sMC: D. The PERSIST study is acknowledged. But long-term efficacy and safety data are considered necessary for chronic conditions and data beyond 48 weeks are limited. iPT: D. Absence of long-term efficacy data to prove maintenance of positive effects accepted. Monitor the efficacy in patients receiving treatment. nCPE: D. Absence of long-term efficacy and safety data not accepted. 96 weeks in adults and 72 in children considered limited. Has: D. Absence of long-term efficacy data to prove maintenance of positive effects accepted. iQWig: ND.
Clinical added value (Relative Cost-Effectiveness:
The 4th guarantee).
NA.
nHs: D. ICER and QALY. No global budget discussion. Ivacaftor reduces need for other expensive treatments for progressive clinical deterioration and need of hospital care, including organ transplantation, which accounts for £100m annual expenditure (excluding transplantation). The regulatory and Health Technology processes in Europe and drug market access. The case of cystic fibrosis of this expensive treatment in their public health systems.
Nevertheless, despite the negative recommendations issued by the Scottish Medicines Consortium and the National Center for Pharmacoeconomics of Ireland, the governments of these two countries finally decided to make the drug available, being the decision ultimately raised to the political level.
It is also to be mentioned that outside the EU, similar conclusions were reached. The Canadian Drug Expert Committee (CDEC) recommended in March 2013 ivacaftor under the condition of a substantial reduction in price to meet cost-effectiveness criteria [16] . The Pharmaceutical Benefits Advisory Committee (PBAC) in Australia reflected in March 2014 that without a substantial price reduction or a pay for performance arrangement, ivacaftor would not be considered costeffective [17] .
conclusIon
The case of Kalydeco exemplifies the dilemma between the scientific clinical evidence and the national budget considerations that HTA bodies face. Kalydeco was undoubtedly and unanimously recognized at EU level by regulators on the three first basic guarantees. However, the granting of an EU marketing authorization is not to be taken for granted as synonym of equal access to European patients. Some national HTA bodies can conclude that financing and reimbursement requirements are not met and therefore block entrance into their respective markets.
In such a situation, will the disharmony among European countries be solved if a common core HTA method and efficient sharing of data were established among HTA bodies? The example of Kalydeco evidences that the solution might not be so simple, as it is clear that the clinical evidence can be overruled by price and budget considerations. In the last two decades, regulatory agencies have enormously increased the level of harmonization, communication and transpa-
dIscussIon
From the point of view of the scientific evidence, all the HTA reports analysed obtained the main clinical elements regarding safety and efficacy from the published EPAR (Table  IV) . None of the HTA reports challenged the design of the studies or the clinical evidence generated.
However, there was a clear difference in the way the existing degree of uncertainty was evaluated, being this aspect the key point in the justification of the negative opinions reached by the Irish and Scottish HTA bodies. All HTA reports alluded to the presence of uncertainty regarding long term effects. In fact, this aspect is well reflected in the EPAR.
The EMA opinion noted the limited data on longer-term effects and as a result imposed conditions on the marketing authorization in this respect (provision of on-going long-term study and the conduct of a five-year observational study). However, while for NHS England, Spain, France and Germany this degree of uncertainty was considered acceptable and did not preclude a positive financing decision, for the Scottish and Irish HTA bodies this represented the scientific clinical evidence factor highlighted and emphasized in order to support the negative opinion. ensure predictability and facilitate as much as possible patient's early access to new medicines. A disharmony in this area would also raise controversy across patient' organizations as it will become difficult to justify that in the framework of the European Union not all patients enjoy the same degree of health protection. However, in this subject of access and equity, not only regulators should be seen as the only responsible party. Industry also has a responsible role to play. Regulators and HTA bodies are taking important steps and efforts to harmonize criteria and are willing to embark in a transparent dialogue with industry to facilitate the development of new drugs. But at the same time, sponsors of the new medicines also need to be aware of the European governments' obligation to assure the long term sustainability of their health systems.
rency in relation to their assessment processes. HTA bodies in Europe are now working to achieve the same degree of harmonization and collaboration for HTA process and find a common path where both evaluation meet and align. However, the local focus that the financing perspective has cannot be obviated and as a result, different national conclusions can arise from the same clinical evidence. Some of them could be due to the selection of different factors for the analysis or the outcome of the importance and interpretation given based on local specificities and values or on national cost-effectiveness thresholds and budget's restrictions.
Regulators and HTA bodies are aware of the need to provide industry with clear guidelines for the development of new medicines and are willing to engage in a transparent and productive dialogue with industry in order to references
